By Ben Glickman
Taysha Gene Therapies will discontinue development of its TSHA-120 program to treat giant axonal neuropathy after receiving feedback from the U.S. Food and Drug Administration.
The Dallas-based gene-therapy developer said that it had received Type C meeting feedback from the FDA. Chief Executive Sean Nolan said that the feedback…
Read the full article here
